Last Updated: November 9, 2026

Details for New Drug Application (NDA): 020240

NDA 020240 describes RENORMAX, which is a drug marketed by Schering and is included in one NDA. Additional details are available on the RENORMAX profile page.

The generic ingredient in RENORMAX is spirapril hydrochloride. There is one drug master file entry for this compound. Additional details are available on the spirapril hydrochloride profile page.

Summary for 020240

Tradename:	RENORMAX
Applicant:	Schering
Ingredient:	spirapril hydrochloride
Patents:	0

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	3MG
Approval Date:	Dec 29, 1994	TE:		RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	6MG
Approval Date:	Dec 29, 1994	TE:		RLD:	No

Profile for product number 003

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	12MG
Approval Date:	Dec 29, 1994	TE:		RLD:	No

Expired US Patents for NDA 020240

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Schering	RENORMAX	spirapril hydrochloride	TABLET;ORAL	020240-001	Dec 29, 1994	⤷ Start Trial	⤷ Start Trial
Schering	RENORMAX	spirapril hydrochloride	TABLET;ORAL	020240-004	Dec 29, 1994	⤷ Start Trial	⤷ Start Trial
Schering	RENORMAX	spirapril hydrochloride	TABLET;ORAL	020240-003	Dec 29, 1994	⤷ Start Trial	⤷ Start Trial
Schering	RENORMAX	spirapril hydrochloride	TABLET;ORAL	020240-002	Dec 29, 1994	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.